Proton Therapy, Heavy-Ion Therapy & CAR-T: Who Actually Qualifies — and Who Does Not

1. Why "New" Does Not Mean "For Everyone": The Fundamental Principle of Advanced Therapy Indications

When a cancer patient or their family first encounters the terms proton therapy, heavy-ion therapy, or CAR-T cell therapy, the natural response is a combination of hope and urgency. These are genuinely remarkable medical technologies — among the most sophisticated therapeutic tools that oncology has ever produced. Media coverage is almost universally positive, clinical centers market them assertively, and patient communities discuss them with the kind of reverence once reserved for miracle cures. The excitement is understandable. In the right patient, these therapies can achieve outcomes that were simply impossible a generation ago.

But here is the critical truth that every patient and family member must internalize before taking another step: the innovation of a therapy and its appropriateness for any given individual are completely separate questions. A technology can be genuinely transformative in medicine while simultaneously being entirely inappropriate — or even dangerous — for a particular patient. This is not a marginal caveat. It is the central clinical reality governing all three of these therapies, and failing to understand it leads directly to wasted resources, missed opportunities for genuinely effective alternatives, and in some cases, real harm.

The indications — the specific clinical criteria defining which patients benefit from a given treatment — for proton therapy, heavy-ion (carbon-ion) therapy, and CAR-T cell therapy are precise, demanding, and non-negotiable. They were developed through thousands of clinical trials, peer-reviewed by international oncology bodies, and refined over decades of clinical practice. When a world-class oncologist tells a patient that they are not a candidate for one of these treatments, that is not a failure of medicine. It is medicine working correctly — protecting a patient from a treatment that would not help them and ensuring they receive the therapy that actually will.

This article exists to give you the clearest, most honest picture available of what qualifies a patient — and what disqualifies them — for each of these three transformative therapies. It is written for adults in North America and Europe who are navigating cancer diagnoses, supporting loved ones through treatment decisions, or exploring international medical options through platforms like MedBridge. Our goal is not to generate enthusiasm. Our goal is to give you the accurate information that allows you to ask the right questions and make genuinely informed decisions.

1.1 The Distinction Between Availability and Appropriateness

Across North America and Europe, the expansion of proton therapy centers has been dramatic over the past decade. There are now more than 40 operational proton therapy facilities in the United States alone, with additional centers across Germany, the United Kingdom, France, the Netherlands, and the Nordic countries. Heavy-ion therapy centers remain far rarer — fewer than 15 globally — with major facilities concentrated in Japan, Germany, and increasingly in China, where significant government investment has made the country home to several of the world's newest and most technologically advanced carbon-ion facilities. CAR-T therapy is available at major academic medical centers across the US and Europe, with expanding capacity in China's top oncology hospitals.

Availability, however, is not the same as appropriateness. The existence of a proton center near you does not mean proton therapy is the right treatment for your cancer. The existence of a cutting-edge carbon-ion facility in another country does not mean traveling there will benefit you. A CAR-T program at a world-class hospital does not mean you are eligible for that program. Every single one of these treatments requires rigorous pre-treatment evaluation to determine whether the specific combination of your tumor characteristics, disease stage, prior treatment history, organ function, performance status, and personal circumstances places you in the group that genuinely benefits.

MedBridge was built precisely to help international patients navigate this complexity honestly — not to market treatments, but to connect patients with the specialists who can provide accurate, individualized assessments and then support the logistics of accessing the right care wherever in the world that care is best delivered.

1.2 Why International Patients Are Particularly Vulnerable to Misinformation

International patients — those traveling across borders for cancer treatment — face a specific and well-documented vulnerability: the combination of desperation, information asymmetry, and aggressive marketing by some providers creates conditions where patients may pursue treatments they do not actually need, or for which they are not appropriate candidates, at enormous financial and physical cost. Studies of medical tourism in oncology have documented cases of patients traveling internationally for proton therapy for cancers where conventional radiotherapy would have produced equivalent outcomes, or pursuing CAR-T consultations despite disease characteristics that clearly preclude candidacy.

This is why MedBridge's approach begins with education and honest assessment — before any clinical recommendation is made. The sections that follow provide the most accurate public-domain summary of indications and contraindications for each therapy currently available. Read them carefully. Use them to ask better questions of every clinician you consult.

2. Proton Therapy Explained: How It Works and Who It Is Genuinely Designed For

Proton therapy is a form of external-beam radiation therapy that uses protons — positively charged subatomic particles — rather than conventional X-rays (photons) to deliver radiation to tumors. The fundamental physical difference between proton beams and conventional photon beams produces a profoundly important clinical distinction: protons release the vast majority of their energy at a very precise depth within tissue — a phenomenon called the Bragg peak — and then stop abruptly, depositing almost no energy beyond the tumor target. Conventional photon radiation, by contrast, deposits energy continuously as it passes through all tissues, entering through healthy tissue, delivering maximum dose to the tumor, and then continuing through to exit the body on the other side, irradiating healthy structures along the entire exit path.

This physical advantage translates into a genuine clinical benefit — but only when the anatomical relationship between the tumor and surrounding critical structures actually justifies it. For many cancers, the Bragg peak advantage does not produce meaningfully better clinical outcomes than modern photon techniques such as intensity-modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT). The evidence for clinical benefit is strongest — and the indication clearest — in situations where sparing the surrounding tissue from radiation dose produces a measurable reduction in toxicity or enables dose escalation that improves tumor control.

2.1 Established and Strong Indications for Proton Therapy

The clinical evidence base for proton therapy is strongest, and the indications most clearly established, in the following patient categories. These represent situations where the physics of proton delivery translates into documented clinical benefit:

• Pediatric cancers of all types: Children have the longest life expectancy ahead of them after treatment, making the long-term effects of radiation — including second malignancies, cognitive effects, cardiac toxicity, and growth disruption — critically important to minimize. For pediatric brain tumors, spinal cord tumors, and many other childhood cancers, proton therapy represents the clearest and most broadly accepted indication. Pediatric oncology guidelines from major international bodies including the Children's Oncology Group increasingly incorporate proton therapy as a preferred or standard-of-care approach for specific diagnoses.
• Base-of-skull tumors and chordomas: Chordomas and chondrosarcomas arising at the base of the skull and along the spine are located adjacent to critical structures including the brainstem, optic pathways, and spinal cord. These tumors require high radiation doses for effective control — doses that conventional photon radiation cannot safely deliver without exceeding the tolerance of adjacent structures. Proton therapy's superior dose conformality allows dose escalation while respecting critical structure constraints. This indication has the longest clinical history and strongest evidence base in proton oncology.
• Ocular melanoma (uveal melanoma): Proton therapy for uveal melanoma — delivered at low energies targeting the eye — achieves local tumor control rates equivalent to enucleation (surgical eye removal) while preserving the eye in the majority of patients. This is one of the oldest and most established proton therapy indications, with over four decades of clinical evidence.
• Paranasal sinus and nasal cavity tumors: Rare tumors of the sinuses and nasal cavity, including olfactory neuroblastoma and sinonasal undifferentiated carcinoma, are adjacent to the optic nerves, brain, and other critical structures. Proton therapy's dose conformality is particularly valuable in this complex anatomical region.
• Prostate cancer in specific clinical contexts: For prostate cancer, the clinical evidence comparing proton therapy to modern photon-based techniques including IMRT remains an area of ongoing debate. The most clearly supported indication is in patients where minimizing rectal and bladder dose is clinically prioritized — particularly younger patients with very long life expectancy or those with specific anatomical factors. Proton therapy is not universally superior to IMRT for prostate cancer in all patients.
• Breast cancer requiring chest wall/nodal irradiation with cardiac proximity: In left-sided breast cancer patients requiring radiation to the chest wall and regional lymph nodes, proton therapy can substantially reduce cardiac dose compared to photon techniques, potentially reducing long-term cardiotoxicity. This is particularly relevant for younger patients, those with pre-existing cardiac conditions, or anatomical configurations that bring the heart into the radiation field.
• Esophageal and thoracic malignancies: For esophageal cancer and some thoracic tumors, proton therapy's ability to reduce dose to the lungs, heart, and spinal cord compared to photon techniques has demonstrated benefits in reducing treatment-related toxicity in selected patients.

2.2 Who Is NOT an Appropriate Proton Therapy Candidate

This section is as important as the indications above — perhaps more so for patients who have self-identified as potential candidates based on incomplete information:

• Widespread metastatic disease: When cancer has spread to multiple sites throughout the body, the rationale for precise local radiation therapy — which is what proton therapy provides — is fundamentally undermined. Proton therapy treats a specific, localizable target. It cannot address systemic disease. Patients with extensive metastatic spread are typically better served by systemic therapies.
• Tumors in locations where photon techniques are equally effective and safe: For many tumor locations and patient anatomies, modern photon-based techniques including IMRT and SBRT achieve dose distributions that are equivalent to proton therapy in terms of both tumor dose and critical structure sparing. In these cases, the higher cost of proton therapy is not justified by a clinical advantage.
• Patients with implanted cardiac devices in the beam path: Certain cardiac pacemakers and implantable cardioverter-defibrillators can malfunction when exposed to proton beams. This is a relative contraindication that requires careful evaluation by the treating team.
• Active inflammatory bowel disease in the treatment field: For pelvic tumors, active inflammatory bowel disease significantly increases radiation-related gastrointestinal toxicity regardless of modality, and may preclude proton therapy in some cases.
• Tumors with poorly defined margins on imaging: The precision of proton therapy is its greatest strength, but it requires precise target definition. Tumors with indistinct or infiltrative margins that cannot be accurately delineated on planning imaging may not be suitable candidates.

2.2.1 The "Proton vs. Photon" Decision: When Does the Physics Advantage Translate to Clinical Benefit?

The central question in proton therapy decision-making is not whether proton therapy is more physically precise than photon techniques — it is. The question is whether that physical precision translates into a clinically meaningful difference in outcomes for the specific patient being evaluated. This determination requires comparative treatment planning — a process in which both a proton plan and the best achievable photon plan are generated for the individual patient's tumor, and the dose to critical structures is compared. In cases where the dosimetric difference between the two plans is small, the clinical rationale for proton therapy weakens significantly. In cases where the proton plan achieves substantially lower dose to organs at risk, the rationale strengthens accordingly. MedBridge's partner oncology centers perform this comparison routinely as part of the eligibility evaluation process.

3. Heavy-Ion Therapy: The Pinnacle of Particle Radiation — and Its Exceptionally Strict Patient Gates

Heavy-ion therapy — most commonly referring to carbon-ion therapy, though helium-ion and oxygen-ion therapy are also in clinical development — represents the frontier of particle radiation oncology. Like proton therapy, carbon-ion therapy exploits the Bragg peak to deliver radiation with high geometric precision and sharp dose falloff beyond the target. But carbon ions offer two additional properties that protons cannot match: higher linear energy transfer (LET) and therefore greater biological effectiveness per unit of physical dose, and superior Bragg peak sharpness with even less lateral penumbra. In practical terms, this means carbon-ion therapy can be biologically more destructive to tumor cells per unit of radiation delivered, and can achieve this destruction with extreme geometric precision.

These properties make carbon-ion therapy potentially superior to proton therapy — and dramatically superior to conventional photon radiation — for specific tumor types with particular biological characteristics. However, the same properties that make it powerful make its appropriate use demanding. Carbon-ion therapy is not simply "proton therapy but better." It is a fundamentally different biological tool with distinct indications, distinct toxicity profiles, and distinct patient requirements. Applying it outside its established indications carries real risks of over-treatment and can actually produce worse outcomes than conventional approaches in the wrong patient.

3.1 Established Indications for Carbon-Ion (Heavy-Ion) Therapy

The evidence base for carbon-ion therapy, while growing rapidly, remains more limited than that for proton therapy simply because heavy-ion facilities have been fewer in number and the technology younger. The strongest established indications, recognized by major international particle therapy bodies including PTCOG (Particle Therapy Co-operative Group), include:

• Chordomas and chondrosarcomas (skull base and spine): These are the flagship indications for carbon-ion therapy. Carbon ions' high LET is particularly effective against these characteristically radiation-resistant tumors. Phase II and retrospective data from the Heidelberg Ion-Beam Therapy Center (HIT), NIRS Japan, and China's Shanghai Proton and Heavy Ion Center (SPHIC) demonstrate local control rates substantially superior to conventional photon radiation and comparable or superior to proton therapy for the same indication.
• Locally advanced head and neck cancers — particularly adenoid cystic carcinoma (ACC): ACC of the salivary glands and other head and neck sites is notoriously resistant to conventional radiation. Carbon-ion therapy's high-LET radiation overcomes this radioresistance, and several series have demonstrated improved local control rates. This has become one of the most actively studied and clinically compelling carbon-ion indications.
• Mucosal malignant melanoma of the head and neck: A rare but aggressive tumor type that is largely resistant to conventional photon radiation. Carbon-ion therapy's radiobiological advantage against hypoxic, radiation-resistant tumors makes it a strong candidate for this indication.
• Locally advanced non-small cell lung cancer in selected patients: For patients with medically inoperable locally advanced NSCLC, carbon-ion therapy allows hypofractionated (fewer treatments, higher dose per treatment) schedules that appear to improve local tumor control while maintaining acceptable toxicity. Patient selection for this indication is particularly rigorous and requires careful cardiopulmonary function evaluation.
• Hepatocellular carcinoma (liver cancer) — selected patients: Carbon-ion therapy can deliver ablative doses to liver tumors in few fractions, with the steep dose gradient minimizing hepatic toxicity — critical in patients with underlying cirrhosis whose liver reserve is already compromised. Strict criteria regarding Child-Pugh liver function score, tumor size and number, and prior treatment history govern eligibility.
• Bone and soft-tissue sarcomas — selected unresectable cases: For high-grade sarcomas that cannot be surgically resected with adequate margins, and which are located in anatomical positions where the high LET advantage of carbon ions is relevant, carbon-ion therapy represents a meaningful treatment option.

3.2 Why the Eligibility Bar for Heavy-Ion Therapy Is Exceptionally High

Carbon-ion therapy is available at only approximately 14 facilities worldwide as of 2025. The majority are in Japan, with significant centers in Germany (HIT and MIT Marburg), and China (SPHIC Shanghai, plus newer centers in Lanzhou, Jinan, and Wuhan). The extreme scarcity of these facilities means that treatment slots are genuinely limited, and every slot that goes to an inappropriate candidate is a slot unavailable to a patient who might genuinely benefit. Beyond resource stewardship, the clinical rationale for the strict eligibility criteria is patient safety and outcome optimization:

• Patients with active, uncontrolled systemic disease: Carbon-ion therapy requires treatment over multiple sessions and imposes physiological demands. Patients with uncontrolled cardiac failure, severe COPD, or unmanaged systemic conditions that compromise tolerance of a treatment course may not safely complete therapy.
• Tumors with extensive local or regional spread beyond the conformal radiation field: When tumor extension is so broad that it cannot be encompassed within a radiation volume that spares adequate adjacent normal tissue, the geometric advantage of carbon-ion therapy cannot be safely exploited.
• Prior radiation to the same region at doses approaching normal tissue tolerance: Patients who have received prior high-dose radiation to the same anatomical region may not be eligible for re-irradiation with carbon ions without exceeding cumulative dose constraints for adjacent critical structures. This requires extremely careful dosimetric evaluation on an individual basis.
• Tumor histologies where radioresistance to high LET is not the relevant problem: Not all radioresistant tumors benefit from high-LET radiation. The biological rationale for carbon-ion therapy is strongest for tumors with specific characteristics including low alpha/beta ratio, hypoxic cores, or demonstrated clinical radioresistance to conventional photon radiation.

3.2.1 China's Role as the New Global Center for Heavy-Ion Therapy Access

For international patients — particularly those from North America and Europe — China has emerged as the most accessible destination for heavy-ion therapy. The United States currently has no operational carbon-ion facility. European facilities, while excellent, have long waiting lists and strict eligibility protocols that often prioritize local patients. China's multiple operating and developing heavy-ion centers, combined with significantly lower treatment costs (typically $25,000–$60,000 all-inclusive versus $80,000–$150,000+ in Europe), make it the most practical destination for eligible international patients. MedBridge has established direct relationships with several of China's leading particle therapy centers, enabling rigorous pre-qualification assessments for international patients before any commitment to travel.

4. CAR-T Cell Therapy: A Cellular Revolution With Exceptionally Precise Patient Requirements

CAR-T cell therapy — Chimeric Antigen Receptor T-cell therapy — is categorically different from both proton and heavy-ion therapy. It is not a radiation treatment at all. It is a form of living cell therapy in which a patient's own T-cells (a type of immune cell) are extracted from their blood, genetically engineered in a laboratory to express a synthetic receptor targeting a specific protein on cancer cells, expanded into tens of millions of copies, and then infused back into the patient where they seek out and destroy cancer cells expressing the target antigen. When it works in the right patient, it can produce complete, durable remissions in cancers that were previously considered uniformly fatal after relapse. It is, in the truest sense, a paradigm shift.

But CAR-T therapy carries the most demanding eligibility requirements of all three therapies discussed in this article — requirements driven by both its narrow approved indications and its potentially severe and life-threatening toxicity profile. CAR-T cell therapy is currently approved only for specific hematological (blood) cancers, and even within those cancer types, only for patients who meet detailed eligibility criteria related to their specific disease subtype, prior treatment history, performance status, and organ function.

4.1 Currently Approved Indications for CAR-T Cell Therapy

As of mid-2025, the FDA-approved CAR-T products cover the following specific indications. Similar approvals exist from the European Medicines Agency (EMA) and China's National Medical Products Administration (NMPA). The list has expanded significantly since the first approval in 2017 and continues to grow:

• Relapsed or refractory large B-cell lymphoma (LBCL) — after ≥2 prior lines of therapy: This was the original approved indication for CAR-T therapy and includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma transformed to DLBCL. Multiple products are approved in this space including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel). More recently, approvals have been extended to second-line treatment for patients whose disease is refractory or relapsed within 12 months of first-line chemoimmunotherapy.
• Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) — in children and young adults: Tisagenlecleucel is approved for patients up to age 25 with relapsed or refractory B-ALL. This remains one of the most compelling CAR-T success stories, with complete remission rates exceeding 80% in appropriate candidates.
• Relapsed or refractory multiple myeloma — after ≥4 prior lines of therapy: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) target BCMA (B-cell maturation antigen) and are approved for heavily pretreated multiple myeloma patients. Cilta-cel approval has been expanded to earlier lines in some regulatory jurisdictions. This indication represents one of the fastest-evolving areas of CAR-T development.
• Relapsed or refractory follicular lymphoma — after ≥2 prior lines of therapy: Axi-cel received approval for this indication, representing an expansion of CAR-T therapy into indolent lymphomas.
• Relapsed or refractory mantle cell lymphoma: Brexucabtagene autoleucel (brexu-cel) is approved for this indication.

4.2 The Detailed Eligibility Requirements Within Approved Indications

Even within the approved indications listed above, not every patient with relapsed DLBCL or refractory myeloma is an appropriate CAR-T candidate. The eligibility requirements within each indication are detailed and demanding:

• Performance status: Most CAR-T programs require an ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, and a maximum of 2 in some protocols. Patients with significant functional limitations from their cancer or other conditions may not tolerate the treatment and recovery process.
• Adequate organ function: Hepatic function (typically ALT/AST ≤5× upper limit of normal, bilirubin ≤2× ULN), renal function (creatinine clearance ≥30–60 mL/min depending on protocol), cardiac function (left ventricular ejection fraction ≥40–50%), and pulmonary function are all evaluated as minimum thresholds.
• Adequate bone marrow function: Patients must have sufficient bone marrow reserve to safely undergo the leukapheresis (cell collection) process and tolerate the lymphodepleting chemotherapy administered prior to CAR-T infusion.
• No active, uncontrolled infection: Active systemic infections — bacterial, viral, or fungal — represent significant safety concerns during CAR-T treatment, which involves profound immunosuppression.
• No active autoimmune disease requiring systemic immunosuppression: Systemic corticosteroids and other immunosuppressive agents can impair CAR-T cell function and reduce response rates. Active autoimmune conditions requiring these treatments may preclude CAR-T eligibility.
• Prior stem cell transplant — specific timing considerations: Allogeneic (donor) stem cell transplant recipients have additional eligibility considerations related to graft-versus-host disease activity, time since transplant, and immunosuppression levels.
• Adequate CAR-T cell manufacturing: The CAR-T manufacturing process itself can fail — particularly in heavily pretreated patients whose T-cells may be functionally exhausted or quantitatively depleted. Pre-leukapheresis assessment of T-cell health is increasingly incorporated into eligibility evaluation.

4.3 The Critical Toxicity Landscape: Why Medical Oversight Is Non-Negotiable

CAR-T therapy can produce two distinctive and potentially life-threatening toxicity syndromes that require immediate, expert management in a specialized clinical setting. These toxicities are among the most serious in all of oncology and represent a primary reason why CAR-T therapy must be administered only at certified, experienced centers with dedicated monitoring infrastructure:

4.3.1 Cytokine Release Syndrome (CRS): The Most Common Serious CAR-T Toxicity

CRS occurs when the massive activation of CAR-T cells triggers a systemic inflammatory response involving the release of large quantities of cytokines — signaling proteins that coordinate immune responses. Mild CRS (grade 1–2) resembles a severe flu syndrome with fever, fatigue, and myalgias. Severe CRS (grade 3–4) can produce life-threatening hypotension, respiratory failure requiring mechanical ventilation, and multi-organ dysfunction. The management of severe CRS — including the use of the IL-6 receptor antagonist tocilizumab and corticosteroids — requires round-the-clock monitoring in an ICU-capable setting by physicians experienced with this syndrome. Centers not certified for CAR-T administration cannot safely manage this complication.

4.3.2 Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS): The Neurological Risk

ICANS is a neurological syndrome that can follow CRS, manifesting as confusion, aphasia (difficulty speaking), tremor, and in severe cases, cerebral edema that can be fatal. Grading and management of ICANS follows established protocols, but requires immediate recognition and expert intervention. The risk of ICANS varies by CAR-T product and patient characteristics, and is a critical factor in the pre-treatment risk-benefit discussion that every CAR-T candidate must have with their treating team.

5. Side-by-Side: Eligibility Criteria Across All Three Advanced Therapies

The following comparison table synthesizes the key eligibility parameters across proton therapy, heavy-ion (carbon-ion) therapy, and CAR-T cell therapy. It is designed as a reference framework — not a substitute for individual clinical evaluation — to help patients understand where they might focus their discussions with specialists.

5.1 The "Combination Approach" Question: Can These Therapies Be Used Together?

A question frequently raised by patients and families is whether these advanced therapies can be combined — for example, using proton therapy to treat a primary tumor site while simultaneously pursuing CAR-T therapy for systemic disease. In general, combining radiation-based therapies with active CAR-T treatment is approached with great caution. Radiation delivered during or immediately after CAR-T infusion can damage the CAR-T cells themselves, impair their trafficking to tumor sites, and exacerbate toxicity syndromes. The timing of any radiation therapy relative to CAR-T administration requires careful coordination between radiation oncologists and cellular therapy specialists. MedBridge facilitates exactly this kind of multidisciplinary coordination for patients with complex multi-modality treatment questions.

The combination of proton therapy and heavy-ion therapy is generally not applicable — a patient would typically receive one form of particle therapy for a given treatment course. However, re-irradiation with heavy-ion therapy in a patient who previously received proton therapy may be considered in carefully selected cases, with detailed dosimetric evaluation of cumulative dose to normal structures.

6. Red Flags and Absolute Contraindications Every Patient and Family Must Know

This section addresses the conditions under which pursuing any of these three therapies would be not merely ineffective but actively inappropriate — situations where a reputable clinical center will and should decline to treat, and where the ethical responsibility of an advisory service like MedBridge is to clearly communicate this reality to inquiring patients rather than simply refer them forward.

6.1 Universal Red Flags Across All Three Therapies

• An unverified or incomplete diagnosis: None of these therapies should be initiated without a confirmed, pathologically verified diagnosis from a qualified pathology laboratory, including appropriate molecular, genetic, and immunohistochemical characterization. Patients who are pursuing advanced therapies based on imaging findings alone, without confirmed histology, are not appropriate candidates for treatment planning — for any of these modalities.
• Significant performance status decline (ECOG 3–4): Patients who are bedridden for more than 50% of waking hours, or who are completely dependent for self-care, are at substantially elevated risk of treatment-related mortality across all three therapies. The benefit-to-risk calculation shifts dramatically in patients with severe performance status decline, and the honest clinical recommendation is usually best supportive care or participation in appropriately designed trials.
• Patient or family-driven urgency overriding clinical evaluation: Some of the most harmful decisions in oncology occur when urgency — understandable, human, and deeply sympathetic — leads to bypassing the evaluation process. Reputable providers of all three therapies require adequate pre-treatment evaluation time. Providers who promise to expedite treatment without adequate evaluation should be treated with significant caution.
• Financial exploitation of terminal diagnosis: Patients with advanced cancer who are offered access to experimental or off-label versions of these therapies outside of proper clinical trial frameworks, particularly for large upfront fees, deserve protection. MedBridge's vetting process specifically screens partner centers for ethical treatment-offering practices.

6.2 Proton-Specific Absolute Contraindications

• Active pregnancy — radiation exposure to the fetus is the primary concern
• Prior irradiation of the same volume at or near tissue tolerance doses, without adequate dosimetric evaluation demonstrating safe cumulative constraints
• Certain metallic implants or prostheses within or near the planned beam path that cannot be adequately characterized in treatment planning systems

6.3 Heavy-Ion Therapy Specific Absolute Contraindications

• Histologically confirmed tumor types where high-LET radiation provides no biological advantage over photon or proton therapy — the cost and complexity of heavy-ion therapy is not justified
• Tumors invading or directly abutting radiosensitive critical structures where the planned target dose would inevitably exceed safe biological effective doses to those structures
• Patient inability to maintain positioning reproducibility during treatment sessions — a concern in patients with severe pain, spasticity, or cognitive impairment

6.4 CAR-T Cell Therapy Specific Absolute Contraindications

6.4.1 The Emerging Frontier: When "Not Yet Approved" Does Not Mean "Never"

For patients with solid tumors who are asking about CAR-T therapy — an increasingly common inquiry — the honest answer in 2025 is: approved CAR-T therapy is not available for your cancer type, but clinical trials may be. Dozens of Phase I and Phase II trials are actively investigating CAR-T constructs targeting antigens expressed in solid tumors including HER2, mesothelin, EGFR, GD2, and others. Participation in these trials at qualified research centers represents the only legitimate pathway for solid tumor patients interested in CAR-T approaches. MedBridge can facilitate connections to appropriate trial programs at partner research centers in both Western countries and China, where the volume of CAR-T trial activity has expanded dramatically.

7. The Evaluation Journey: How Candidacy for These Therapies Is Actually Determined Step by Step

Understanding what the eligibility evaluation process actually looks like in practice is essential for patients considering these therapies. Many patients arrive at consultations with unrealistic expectations about the speed and simplicity of candidacy determination. The reality is that eligibility for each of these therapies requires a structured, multi-step evaluation process that takes time, requires specific data, and involves multiple specialists. Rushing or bypassing any element of this process is a warning sign — not a feature — of any provider offering unusually quick access.

7.1 The Proton and Heavy-Ion Therapy Evaluation Process

7.2 The CAR-T Cell Therapy Evaluation and Manufacturing Process

The CAR-T evaluation process is unique in oncology because it involves not only patient assessment but also a manufacturing step that takes time and can fail. The full process from initial evaluation to CAR-T infusion typically requires 4–8 weeks:

8. Accessing These Therapies Internationally Through MedBridge: Honest Navigation for Complex Decisions

For patients in North America and Europe exploring proton therapy, heavy-ion therapy, or CAR-T cell therapy through international channels, the landscape of providers, cost structures, eligibility standards, and support infrastructure is genuinely complex. MedBridge was built to navigate exactly this complexity — not to advocate for any particular treatment or destination, but to ensure that every patient receives honest clinical assessment, access to the right specialists, and comprehensive logistical support if treatment is determined to be appropriate.

8.1 Why International Access Often Matters Most for Heavy-Ion Therapy

For patients who genuinely qualify for heavy-ion (carbon-ion) therapy, the international access question is particularly acute. The United States has no operational carbon-ion facility. European centers — HIT in Heidelberg, MIT in Marburg, CNAO in Pavia, and the MedAustron center in Austria — are excellent but have long waiting lists and prioritize domestic and EU patients. Japan's centers (NIRS/QST, Gunma, Kanagawa, and others) are world-class but represent significant logistical complexity and cost for Western patients. China has emerged as the most accessible and cost-effective destination for eligible international patients seeking carbon-ion therapy, with multiple operating facilities including the Shanghai Proton and Heavy Ion Center (SPHIC), the Wuwei Carbon-Ion Therapy Center, and the Lanzhou Heavy Ion Hospital, with additional centers operational or in commissioning phase.

8.2 CAR-T Therapy Internationally: A Complex but Increasingly Viable Landscape

CAR-T therapy for eligible patients represents perhaps the most complex international medical navigation challenge of any therapy discussed in this article. The manufacturing dependency means that cell collection and infusion must be carefully coordinated — typically at the same certified center. China's regulatory environment has moved rapidly in CAR-T, with multiple domestic CAR-T products approved by the NMPA and several major academic oncology centers operating full CAR-T programs. For patients from Western countries who are eligible for CAR-T therapy, accessing treatment in China may offer significant cost advantages — approved CAR-T products in China are priced substantially below their US and European equivalents, and the clinical quality at top-tier centers such as those affiliated with Beijing, Shanghai, and Guangzhou medical universities is genuinely world-class.

However, the logistical requirements are substantial: patients must be prepared for a minimum 6–8 week stay, must have all medical records formally translated and evaluated, must coordinate the manufacturing timeline with travel logistics, and must have clear contingency plans for managing toxicities in a non-home-country medical environment. MedBridge's role in this context is to provide the coordination infrastructure that makes this manageable — and to be honest with patients when their clinical profile suggests they are not appropriate candidates, even when that is not what they hope to hear.

8.3 The MedBridge Pre-Evaluation Process for Advanced Therapy Candidates